All Glioblastoma Are Not Equal: Distinct Spatial Immune Profiles Between De Novo and Recurrent Tumors.

Lack of insight into the immunosuppressive microenvironment of glioblastoma (GBM) hinders successful application of immunotherapy. In this issue, Alanio and colleagues identify a distinct T-cell localization profile between recurrent and de novo GBM highlighting the importance of spatial heterogeneity and providing new avenues to explore to improve GBM outcome. See related article by Alanio et al., p. 800 (3).